LAUSR

BACKGROUND Tumor necrosis factor receptor-related factor 3 (TRAF3) interacting protein 3 (TRAF3IP3) is involved in the development of immune tissues and the immune response of the body. Down-regulated expression of TRAF3IP3 in malignant melanoma can inhibit tumor growth. The role of TRAF3IP3 in glioma is unknown. METHODS We used the Wilcoxon rank sum test to compare the expression of TRAF3IP3 in glioma and normal tissues based on TCGA and GTEx. Logistics regression were used to evaluate the relationship between TRAF3IP3 and clinicopathological characters. Gene Set Enrichment Analysis (GSEA) and single sample GSEA (ssGSEA) was conducted to annotate biological function of TRAF3IP3. We used Kaplan-Meier and COX regression to evaluate the prognostic value of TRAF3IP3. RESULTS We downloaded RNA-Seq data of 670 gliomas and 1157 normal tissues. TRAF3IP3 was highly expressed in gliomas(P<0.001). High expression of TRAF3IP3 and higher WHO grade (OR=3.57(2.42-5.34), P<0.001), wild-type isocitrate dehydrogenase (IDH) status (OR=4.79(3.40-6.83), P<0.001), 1P /19q non-codeletion (OR=15.32 (9.23-27.01), P<0.001), mutant epidermal growth factor receptor (EGFR) status (OR=2.77(1.65-4.81), P<0.001), worse histological type (OR=3.64(2.48-5.43), P<0.001) and worse primary therapy outcome (OR=2.29(1.47-3.61), P<0.001) were significantly correlated. Six signaling pathways were significantly enriched in the TRAF3IP3 high expression phenotype group, including JAK-STAT, interferon-γ, apoptosis, P53, programmed cell death protein 1 (PD-1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA4). High expression of TRAF3IP3 was associated with worse PFS (HR=2.39(1.39-3.01), P<0.001), DFS (HR=3.02(2.27-4.01), P<0.001) and OS(HR=2.87(2.20-3.75), P<0.001). CONCLUSIONS TRAF3IP3 play an important role in the occurrence and development of glioma, and may be a potential biomarker for the prognosis of glioma.